Investment Rating - The report gives a "Strong Buy" rating for the company, marking its first coverage [3]. Core Insights - The company is transitioning into a new phase characterized by innovation and internationalization, with a focus on commercializing innovative drugs and expanding into emerging markets [1][7]. - The impact of centralized procurement on core products is expected to stabilize, leading to a recovery in revenue and profit growth starting in 2024 [7][13]. - The company has a robust pipeline of nearly 40 innovative drug candidates, with several expected to launch commercially in 2024 [7][23]. Financial Data and Valuation - Total revenue is projected to decline from 8,013 million in 2023 to 7,469 million in 2024, before increasing to 10,061 million by 2026 [2]. - Net profit is expected to decrease from 2,401 million in 2023 to 1,620 million in 2024, with a recovery to 1,955 million by 2026 [2]. - The company’s PE ratio is forecasted to improve from 18.6 in 2024 to 15.4 in 2026, indicating a potential increase in valuation [2]. Business Model and Strategy - The company has evolved from a CSO model to a full-chain innovative pharmaceutical enterprise, focusing on specialized fields such as dermatology and ophthalmology [11][18]. - The internationalization strategy includes expanding into Southeast Asia and the Middle East, with nearly 20 drug applications submitted in these regions [7][11]. - The company plans to spin off its dermatology business, Demy Pharma, for independent listing, enhancing its focus on specialized markets [7][11]. Product Pipeline and Market Potential - The innovative product pipeline includes five drugs that have already been commercialized, with additional candidates in various stages of development [20][24]. - Key products such as Vifor (for chronic kidney disease) and Y-3 (for acute ischemic stroke) are expected to drive future growth [29][37]. - The company is targeting significant unmet medical needs in the Chinese market, particularly in areas like high phosphorus levels in dialysis patients and rabies passive immunity [31][47].
康哲药业（00867）：创新化+国际化助力商业化龙头迈入新阶段